8 results about "Aβ oligomers" patented technology

This invention discloses a method for preparing NK cells, the NK cells obtained thereby, and their applications. The method includes: sorting NK cells from peripheral blood of an allogeneic donor; culturing them in a serum-free medium containing CD3 monoclonal antibody, CD16 antibody, and IL-2, without the need for a feeder layer; preferably, IL-21 is added for amplification on days 3-5 of culture, and the cells are cultured for 20-40 days. This method yields non-genetically modified NK cells, among which CD56... bright The NK cells comprise >90% of the cell line and highly express a variety of activating and functional molecules. These NK cells effectively clear Aβ oligomers and senescent cells, and alleviate neuroinflammation. In treatment, intracranial injection achieves equivalent or better efficacy with only about 1 / 10th the dose administered intravenously, significantly clearing Aβ deposits in the brains of AD model mice and improving pathology.

The invention discloses calf animal coccus PD13 for improving Alzheimer's disease and application of the calf animal coccus PD13, and relates to the technical field of biology. Experiments prove that in an Alzheimer's disease model mouse induced by injecting A beta oligomer into the brain, the Azococcus calvus PD13 can improve spatial learning and memory disorder and autonomous exploration ability of the AD model mouse and relieve damage to neurons in a hippocampal region of the Alzheimer's disease model mouse, so that the effect of protecting the neurons is achieved, and the Azococcus calvus PD13 can be used for preparing a medicine for treating the Alzheimer's disease. According to the present invention, with the application of the animal coccus calves, the content of glutathione in mouse serum and the enzyme activity of superoxide dismutase are increased, and the content of malondialdehyde is reduced, such that the animal coccus calves provides good prevention and treatment effects on the Alzheimer's disease, and the new approach is provided for developing the Alzheimer's disease-related drugs.

This invention provides an Alzheimer's disease risk assessment system, comprising: a data acquisition module for acquiring test data of subjects, the test data including at least the concentration of Aβ oligomers, APOEε4 gene carrier status data, and multi-domain risk factor data; the multi-domain risk factor data including demographic indicators and clinical data related to Alzheimer's disease risk; a risk assessment module, communicatively connected to the data acquisition module, for taking the test data from the data acquisition module as input, and outputting a risk probability value of the subject having Alzheimer's disease through a pre-trained machine learning model; and a result output module, communicatively connected to the risk assessment module, for comparing the risk probability value with a preset threshold and outputting risk classification information based on the comparison result. This invention is the first to achieve high-precision and high-sensitivity clinical cognitive impairment screening by fusing multidimensional conventional data through a nonlinear model.

Herein is disclosed amphiphilic small molecules with different hydrophobic and hydrophilic fragments that show high M binding affinity to both Aβ plaques and oligomers, and selectively binding Aβ oligomers. These amphiphilic compounds can also label the Aβ species in the brain sections of transgenic AD mice, as shown by immunostaining with an Aβ antibody. Certain amphiphilic compounds were found to alleviate the Cu2+-Aβ induced toxicity in cell viability assays. Additionally, two compounds, ZY-15-MT and ZY-15-OMe, were found to disrupt the interactions between Aβ oligomers and human neuroblastoma SH-SY5Y cell membranes. These studies show compounds with amphiphilic properties that target Aβ oligomers and modulate the Aβ oligomer-cell membrane interactions can be effective as small molecule AD therapeutics. Also, the disclosed amphiphilic dicyanomethylene compounds that can emit in the near-infrared region and chelate copper can be used as early diagnostic agents for AD.

This invention provides the use of a biomarker in the preparation of a risk assessment product for mild cognitive impairment (MCI), wherein the biomarker includes Aβ oligomers. The Aβ oligomer biomarker alone has significant predictive value for MCI, achieving an area under the receiver operating characteristic (AUC) of 0.851 (95% confidence interval: 0.803–0.895) on the test set when distinguishing between cognitively normal and MCI subjects, demonstrating its superior performance in differentiating MCI subjects.

The invention discloses a novel immunosensor capable of realizing trace detection of A beta oligomer as well as a preparation method and application of the immunosensor. The preparation method of the immunosensor comprises the following steps: forming a gold nanoparticle-reduced graphene oxide composite layer; the gold nanoparticle-reduced graphene oxide composite layer is covered with cobalt-molybdenum disulfide composite suspension liquid to form a cobalt-molybdenum disulfide composite layer; covering the cobalt-molybdenum disulfide complex layer with an anti-A beta oligomer antibody solution to obtain an anti-A beta oligomer antibody layer; and covering bovine serum albumin on the anti-A beta oligomer antibody layer, and incubating for 30-60 minutes to obtain the immunosensor. According to test determination, the linear range of the immunosensor constructed by the invention is 1.11 * 10 <-9 > M to 1.11 * 10 <-14 > M, and the detection limit can be as low as 6.87 * 10 <-15 > M.

The present invention relates to the diagnostic use of highly toxic amyloid oligomers. In particular, the present invention relates to the use of the new highly toxic amyloid oligomer Aβo*3F as a target for the diagnosis of early and advanced Alzheimer's disease (AD) and AD-derived mild cognitive impairment (MCI), which is specifically bound by the 3F antibody, is present in the cerebrospinal fluid (CSF), blood and / or brain tissue of AD patients and AD-derived MCI patients and whose levels differ significantly in the CSF, blood and / or brain tissue of AD patients, MCI patients and healthy elderly, is a super-toxic oligomer, is the most dominant toxic component of the Aβ oligomer mixture and has a strong pathogenic effect, playing a key role in the development and progression of AD.

Inventors have shown evidence of VEGF accumulation in extracellular Aβ plaques in the post-mortem brain of patients with Alzheimer's disease (AD) and of the APP / PS1 mouse model of AD. They identified specific binding domains involved in the direct interaction between A0o and VEGF and engineered a peptide that blocks this interaction. The designed peptide binds to Aβ oligomers with high affinity and inhibits the process of Aβ self-aggregation, leading to the blockade of fibrillar aggregation. Furthermore, the peptide prevents soluble Aβ-derived toxins to target synapses in hippocampal neuron cultures and restores long-term potentiation in the hippocampus of the APP / PS1 mouse model of Alzheimer's disease. Thus, these findings have broad implications for preventing and treating diseases with Aβ neurotoxicity such as Alzheimer's disease. Accordingly, the invention relates to a peptide comprising the amino acid sequence KRKKSRYKSWSVYVG (SEQ ID NO: 1).